# EDGAR Filing Document

**Accession Number:** 0001604191
**File Stem:** 0001104659-23-002110
**Filing Date:** 2023-1
**Character Count:** 5449
**Document Hash:** c517109e49e09e40881e2172acdf42f4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-002110.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001104659-23-002110

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** First Wave BioPharma, Inc.
- **CENTRAL INDEX KEY:** 0001604191
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 464993860
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37853
- **FILM NUMBER:** 23516876

**BUSINESS ADDRESS:**
- **STREET 1:** 777 YAMATO ROAD
- **STREET 2:** SUITE 502
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431
- **BUSINESS PHONE:** 561-589-7020

**MAIL ADDRESS:**
- **STREET 1:** 777 YAMATO ROAD
- **STREET 2:** SUITE 502
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AzurRx BioPharma, Inc.
- **DATE OF NAME CHANGE:** 20141103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioPharma d'Azur, Inc.
- **DATE OF NAME CHANGE:** 20140331

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a)**

**of the Securities Exchange Act of 1934 (Amendment No.)**

Filed by the Registrant ⌧

Filed by a Party other than the Registrant ◻

Check the appropriate box:

---

| | |
|:---|:---|
| ◻ | Preliminary Proxy Statement |
| ◻ | Confidential, for Use of the SEC Only (as permitted by Rule 14a-6(e)(2)) |
| ◻ | Definitive Proxy Statement |
| ⌧ | Definitive Additional Materials |
| ◻ | Soliciting Material Pursuant to 14a-12 |

---

**FIRST WAVE BIOPHARMA, INC.**

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

⌧ No fee required. <br> ◻ Fee paid previously with preliminary materials. <br> ◻ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

On January 9, 2023, First Wave BioPharma, Inc. issued the following press release:

**FIRST WAVE BIOPHARMA ANNOUNCES ADJOURNMENT OF SPECIAL MEETING**

BOCA RATON, FL., January 9, 2023 (GLOBE NEWSWIRE) – First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has adjourned its Special Meeting of Stockholders (the "Special Meeting") in order to provide stockholders additional time within which to vote on all proposals.

At this time, there is not present, by remote communication or by proxy, a sufficient number of shares of the Company's common stock to constitute a quorum. The Company's Board of Directors continues to believe that all of the proposals contained in the proxy statement are advisable and in the best interests of the Company's stockholders to consider and act upon. Therefore, the Company adjourned the Special Meeting.

The adjourned meeting will be held at 9:00 a.m. EST on January 13, 2023 at the following url: www.virtualshareholdermeeting.com/FWBI2023SM. The record date for the Special Meeting is December 8, 2022.

**Special Meeting of Stockholders of First Wave BioPharma, Inc.**

The adjourned meeting will be held at 9:00 a.m. EST on January 13, 2023 virtually atwww.virtualshareholdermeeting.com/FWBI2023SM. The Board of Directors unanimously recommends that stockholders vote FOR all proposals on the agenda.

Stockholders may cast their vote live with a proxy specialist by calling toll free at 1-866-407-1875 between the hours of 9:00 a.m. and 10:00 p.m. EST, Monday through Friday.

**About First Wave BioPharma, Inc.** 

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical stage programs built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties. First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). In developing adrulipase, First Wave is seeking to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. The company is also advancing multiple programs involving niclosamide, including FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and FW-CD for Crohn's disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

**For more information:**

First Wave BioPharma, Inc.

777 Yamato Road, Suite 502

Boca Raton, FL 33431

Phone: (561) 589-7020

<u>info@firstwavebio.com</u>

Media contact:

<u>Tiberend Strategic Advisors, Inc</u>.

David Schemelia

(609) 468-9325

<u>dschemelia@tiberend.com</u>